Indefinite Delivery Contract 75D30120D08573
Award Date
7/1/20
Last Date to Order
6/30/21
Federal Agency
CDC Pittsburgh
Awardee
Grifols USA LLC
Ultimate Awardee
Not listed
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The Centers for Disease Control and Prevention awarded Grifols USA LLC an indefinite delivery contract for 2019 adult vaccines. The multiple award IDC has a potential value of $1,602,700 and a period of performance from July 1, 2019 through June 30, 2020. Grifols will supply various adult vaccines to support public health programs through the CDC. As a manufacturer of pharmaceuticals and medical products, Grifols has extensive experience providing specialized drugs, vaccines, immunoglobulins and...
The Centers for Disease Control and Prevention (CDC) awarded a $1,727,800 indefinite delivery contract to Grifols USA LLC, a global healthcare company, to purchase 12 standard adult vaccines. The contract has a one-year period of performance from July 1, 2022 to June 30, 2023 and is not designated with any set-aside provisions. The vaccines are required to have a minimum 12-month shelf life and be delivered within 15 business days of order. The vaccines will support CDC immunization awardees,...
This federal contract indefinite delivery vehicle (IDV) was awarded to Grifols USA LLC by the Department of Health and Human Services (HHS) Centers for Disease Control and Prevention (CDC) to provide a variety of adult vaccines. The contract has a potential value of $1,647,100 and a period of performance from July 1, 2021 to June 30, 2022. The vaccines to be supplied under this IDV include hepatitis, pneumococcal, tetanus/diphtheria, herpes zoster, measles/mumps/rubella, meningococcal, human...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) to Grifols USA LLC, a large pharmaceutical manufacturer. The contract, valued at up to $13.88 million annually, is for the supply of a wide range of pediatric vaccines to support the CDC's Vaccines for Children (VFC) program. The vaccines include routine immunizations such as DTaP, Hib, hepatitis, and MMR, among others. The...
The Centers for Disease Control and Prevention awarded an indefinite delivery contract to Grifols USA LLC to supply 20 standard pediatric vaccines in support of the Vaccines for Children program. The contract utilizes multiple awards with a potential value of $12.2 million and period of performance through March 2022. Vaccines will be ordered via task orders against flexible delivery schedules to meet quantities ranging from a minimum of 100 doses to a maximum of 13 million doses per item. The...
The Centers for Disease Control and Prevention (CDC) awarded an Indefinite Delivery Contract (IDC) worth up to $13,017,750 to Grifols USA LLC for the provision of various pediatric vaccines. The contract has an ultimate completion date of March 31, 2023 and was awarded on April 1, 2022 without any set-aside designations, indicating Grifols' capability as a large business to fulfill substantial federal vaccine requirements. The IDC supports the CDC's Vaccines for Children program and other...
The federal contract IDV award is for the supply of various adult vaccines to the Centers for Disease Control and Prevention (CDC) for the period of July 1, 2023 through June 30, 2024. The contract was awarded to Grifols USA LLC, a global healthcare company specializing in the manufacturing and distribution of plasma-derived medicines and pharmaceutical supplies. The contract has a ceiling value of $1,842,400.00 and includes the supply of 12 different adult vaccines, including hepatitis,...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) to Grifols USA LLC, a global healthcare company and manufacturer of essential plasma-derived medicines and vaccines. The contract, valued at a ceiling of $12,409,500, is for the supply of 20 standard pediatric vaccines to support immunization programs under the Vaccines for Children (VFC) program and Section 317(j) of the...
This indefinite-delivery, indefinite-quantity (IDIQ) contract was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases, to Glaxosmithkline, LLC, a pharmaceutical company, for the purchase of 12 standard adult vaccines. The $172.4 million contract has a one-year period of performance from July 1, 2022 to June 30, 2023 and does not utilize any set-asides. The vaccines, which include influenza, hepatitis, pneumococcal, and...
The federal agency Centers for Disease Control and Prevention (CDC) awarded this multiple-award Indefinite Delivery Contract (IDC) to Glaxosmithkline, LLC, a foreign-owned pharmaceutical company, to provide a range of adult vaccines. The IDC has a ceiling value of $105,311,250 and a period of performance through June 30, 2026. The contract covers the procurement of various adult vaccines, including influenza, hepatitis A and B, HPV, pneumococcal, and meningococcal vaccines. Glaxosmithkline has...